Key result
Oral verapamil reduced the frequency of paroxysmal supraventricular tachycardia compared to placebo.
Why the study?
Does oral verapamil reduce the frequency of episodes in patients with frequent paroxysmal supraventricular tachycardia?
RCT (n=11)
Double-blind
randomized
Does oral verapamil reduce the frequency of episodes in patients with frequent paroxysmal supraventricular tachycardia?
Oral verapamil is safe and effective for the long-term reduction of episode frequency and duration in patients with frequent paroxysmal supraventricular tachycardia.
Answers are grounded in this paper and cite their sources.
Supports oral verapamil for frequent PSVT symptom control; confirms randomized long-term efficacy over placebo.
The effectiveness and safety of orally administered verapamil was tested in 11 patients with frequent paroxysmal supraventricular tachycardia. In a 4-month randomized, double-blind, placebo-controlled trial, the frequency of paroxysmal supraventricular tachycardia fell from 0.3 +/- 0.3 (mean +/- SD) to 0.1 +/- 0.1 episodes per day by patient diary (p less than 0.05) and from 0.7 +/- 0.7 to 0.3 +/- 0.5 episodes per day by Holter monitor (p less than 0.05) for placebo and verapamil treatment periods, respectively. Verapamil caused a decrease in the duration of paroxysmal supraventricular tachycardia (in minutes per day): placebo 27 +/- 51 by dairy, 67 +/- 111 by Holter; verapamil, 3 +/- 3 by diary, 1 +/- 2 by Holter (p less than 0.05). Five patients required a total of 35 pharmacologic cardioversions for sustained tachycardia: two during verapamil and 33 during placebo (p less than 0.001). No verapamil treatment period was shortened due to unacceptable paroxysmal supraventricular tachycardia, but five of 22 placebo treatment periods were shortened (p equal to 0.02). Verapamil was well-tolerated, causing mild constipation in five patients and headache in one. Oral verapamil is both safe and effective in the long-term treatment of patients with paroxysmal supraventricular tachycardia.
No takes yet. Share an insight, caveat, or question.
Mauritson et al. (1982) conducted an RCT in paroxysmal supraventricular tachycardia (n=11). Oral verapamil vs. placebo was evaluated on frequency of paroxysmal supraventricular tachycardia by patient diary (episodes per day) (p=<0.05). Oral verapamil reduced the frequency of paroxysmal supraventricular tachycardia compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: